Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree

International Journal of Molecular Medicine

Volumn 24, Issue 2, 2009, Pages 253-260

  Mukherjee, B ^a   Telang, Nitin ^b   Wong, G Y C ^a  

^a STRANG CANCER PREVENTION CENTER   (United States)

^b Palindrome Liaisons   (United States)

Author keywords

Global gene expression profile; Growth inhibition; Human breast carcinoma cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTROGEN RECEPTOR; TABEBUIA AVELLANDAE EXTRACT; TAHEEBO; UNCLASSIFIED DRUG; CYCLIN B; PLANT EXTRACT; PLANT MEDICINAL PRODUCT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARK; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TABEBUIA; TABEBUIA AVELLANDAE; UNINDEXED SEQUENCE; UPREGULATION; BRAZIL; BREAST TUMOR; CELL CYCLE; CHEMISTRY; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NECROSIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; BRAZIL; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; NECROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLANT BARK; PLANT EXTRACTS; PLANT PREPARATIONS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TABEBUIA; TIME FACTORS;

EID: 70349314605     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000228     Document Type: Article

References (38)

1. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three? Breast Cancer Res Treat 3: 117-127, 1983.
2. Early Breast Cancer Trialist's Collaborative Group (EBCTG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 years survival: An overview of the randomized trials. Lancet 365: 1687-1717, 2005.
3. Rock E and DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133: 3785s-3793s, 2003.
4. Oudin C, Bonnetain F, Boidot R, et al: Patterns of loss of heterozygosity in breast carcinoma during neo-adjuvant chemotherapy. Int J Oncol 30: 1145-1155, 2007.
5. Molassiotis A, Scott JA, Kearney N, et al: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14: 260-267, 2006.
6. Tindle HA, Davis RB, Phillips RS, et al: Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 11: 42-49, 2005.
7. Helyer LK, Chin S, Chui BK, et al: The use of complementary and alternative medicines among patients with locally advanced breast cancer - a descriptive study. BMC Cancer 6: 39-46, 2006.
8. Matthews AK, Sellergren SA, Huo D, et al: Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13: 555-562, 2007.
9. Park BS, Lee HK, Lee SE, et al: Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter Pylori. J Ethnopharmacol 105: 255-262, 2006.
10. Park BS, Kim JR, Lee SE, et al: Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria. J Agri Food Chem 53: 1152-1157, 2005.
11. Son DJ, Lim Y, Park YH, et al: Inhibitory effects of Tabebuia impetiginosa inner bark extract on platelet aggregation and vascular smooth muscle cell proliferation through suppressions of arachidonic acid liberation and ERK1/2 MAPK activation. J Ethnopharmacol 108: 148-151, 2006.
12. Lippman ME, Osborne CK, Knazek R and Young N: In vitro model systems for the study of hormone dependent breast cancer. N Engl J Med 296: 154-159, 1977.
13. Jordan VC: Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24: A3-A16, 2002.
14. Hsieh TC, Lu X, Guo J, et al: Effects of herbal preparation Equigard on hormone responsive and hormone refractory prostate carcinoma cells. Int J Oncol 20: 681-689, 2002.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 25: 402-408, 2001.
16. Monte MR, Benetti R, Buscemi G, et al: The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem 278: 30356-30364, 2003.
17. Yin F, Bruemmer D, Blaschke F, et al: Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23: 4614-4623, 2004.
18. Huynh H, Ng CY, Ong CK, et al: Cloning and characterization of a novel pregnancy-induced growth inhibitor in mammary gland. Endocrinology 142: 3607-3615, 2001.
19. Wang T, Xia D, Li N, et al: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis. J Biol Chem 280: 4374-4382, 2005.
20. Concannon CG, Koehler BF, Reimertz C, et al: Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway Oncogene 26: 1681-1692, 2007.
21. Artal-Sanz M and Tavernarakis N: Proteolytic mechanisms in necrotic cell death and neuro-degeneration. FEBS Lett 579: 3287-3296, 2005.
22. Frigo DE, Basu A, Nierth-Simpson EN, et al: p38 Mitogen-activated protein kinase stimulates estrogen mediated transcription and cell proliferation through the phosphorylation and potentiation of the p160 co-activator glucocorticoid receptor interacting protein1. Mol Endocrinol 20: 971-983, 2006.
23. Creighton CJ, Hilger AM, Murthy S, et al: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911, 2006.
24. Jeffrey KL, Camps M, Rommel C and Mackay CR: Targeting dual-specificity phosphatases: manipulating MAP kinase signaling and immune responses. Nature Rev Drug Disc 6: 391-403, 2007.
25. Rogatsky I, Trowbridge JM and Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclinA-cdk2 complex. J Biol Chem 274: 22296-22302, 1999.
26. Trowbridge JM, Rogasky IO and Garabedian MJ: Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci 94: 10132-10137, 1997.
27. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
28. Schneider J, Huh MM, Bradlow HL and Fishman J: Anti-estrogen action of 2-hydroxyestrone on MCF-7 human breast carcinoma cells. J Biol Chem 259: 4840-4845, 1984.
29. Lottering ML, Haag M and Seegers JC: Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52: 5926-5932, 1992.
30. Telang NT, Katdare M, Bradlow HL and Osborne MP: Cell cycle regulation, apoptosis and estradiol metabolism: Novel end point biomarkers for human breast cancer prevention. J Clin Ligand Assays 23: 130-137, 2000.
31. Suto A, Bradlow HL, Kubota T, et al: Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor suppressing agents. Steroids 58: 215-219, 1993.
32. Telang NT, Bradlow HL and Osborne MP: Effect of Tamoxifen on mammary preneoplasia: relevance to chemopreventive intervention. Cancer Detect Prev 18: 313-321, 1994.
33. Osborne MP: Chemoprevention of breast cancer. Surg Clin North Am 79: 1207-1221, 1999. 34. Cover CM, Hsieh SJ, Cram EJ, et al: Indole-3-carbinol and tamoxifen co-operate to arrest cell cycle of MCF-7 human breast cancer cells. Cancer Res 59: 1244-1251, 1999.
34. Cover CM, Hsieh SJ, Cram EJ, et al: Indole-3-carbinol and tamoxifen co-operate to arrest cell cycle of MCF-7 human breast cancer cells. Cancer Res 59: 1244-1251, 1999.
35. Queiroz ML, Valadares MC, Torello CO, et al: Comparative studies of the effects of Tabebuia avellanedae bark extract and β-lapachone on the hematopoietic response of tumor-bearing mice. J Ethnopharmacol 117: 228-235, 2008.
36. Ueda S, Umemura T, Dohguchi K, et al: Production of anti-tumor-promoting furano-naphthoquinones from Tabebuia avellanedae in cell cultures. Phytochemistry 36: 323-325, 1994.
37. Park BS, Lee KG, Shibamoto T, et al: Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia impetiginosa Martius ex DC). J Agri Food Chem 51: 295-300, 2003.
38. Ueda S, Tokuda H, Hirai K, et al: A novel antitumor compound 2-(1-hydroxyethyl)-5-hydroxynaptho [2, 3-b] furan -4, 9-dione and anti-tumor agents comprising this compound. United States of America, Patent # 5,663,197, 1997.